Dr Ian Dick

Ian completed a BSc in biochemistry at the University of Western Australia. He then worked as a Laboratory Assistant at Murdoch University and then as a Research Assistant in Bone and Mineral Research at the University of Western Australia.  During this time he completed a MMedSci and then a PhD on the physiology of calcium metabolism. He joined NCARD in 2008, initially focusing on biomarker research but in more recent years has been working in bioinformatics, using gene sequencing to identify mutations that may be useful for stimulating the immune response to cancer.

• Boosting antigen targeted therapy against cancer (ATTAC) for malignant mesothelioma

Ian was involved in the Antigen-Targeted Therapy Against Cancer (ATTAC) Program, headed by Professor Bruce Robinson, where he was primarily involved in bioinformatics support. In addition he provided general support in statistical analysis of data to NCARD.

• Ma S, Chee J, Fear VS, Forbes CA, Boon L, Dick IM, Robinson BWS, Creaney J.Pre-treatment tumor neo-antigen responses in draining lymph nodes are infrequent but predict checkpoint blockade therapy outcome. Oncoimmunology. 2019 Nov7;9(1):1684714. doi: 10.1080/2162402X.2019.1684714. PMID: 32002299; PMCID:PMC6959436.
• Sneddon S, Rive CM, Ma S, Dick IM, Allcock RJN, Brown SD, Holt RA, Watson M,Leary S, Lee YCG, Robinson BWS, Creaney J. Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma. Oncoimmunology.2019 Nov 3;9(1):1684713. doi: 10.1080/2162402X.2019.1684713. PMID: 32002298;PMCID: PMC6959430.
• Aston WJ, Hope DE, Cook AM, Boon L, Dick I, Nowak AK, Lake RA, Lesterhuis WJ.Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment. Oncoimmunology. 2019 Jul 13;8(11):e1641390. doi:10.1080/2162402X.2019.1641390. PMID: 31646089; PMCID: PMC6791454.
• Fear VS, Forbes CA, Chee J, Ma S, Neeve S, Celliers L, Fisher SA, Dick I,Creaney J, Robinson BWS. Neo-antigen specific T cell responses indicate the presence of metastases before imaging. Sci Rep. 2019 Oct 10;9(1):14640. doi:10.1038/s41598-019-51317-3. PMID: 31601975; PMCID: PMC6787183.
• Fear VS, Tilsed C, Chee J, Forbes CA, Casey T, Solin JN, Lansley SM, Lesterhuis WJ, Dick IM, Nowak AK, Robinson BW, Lake RA, Fisher SA. Combination immune checkpoint blockade as an effective therapy for mesothelioma. Oncoimmunology. 2018 Jul 30;7(10):e1494111. doi: 10.1080/2162402X.2018.1494111.PMID: 30288361; PMCID: PMC6169578.
• Sneddon S, Dick I, Lee YCG, Musk AWB, Patch AM, Pearson JV, Waddell N, Allcock RJN, Holt RA, Robinson BWS, Creaney J. Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations. Lung Cancer.2018 May;119:64-70. doi:
  10.1016/j.lungcan.2018.03.009. Epub 2018 Mar 9. PMID:29656754.
• Sneddon S, Patch AM, Dick IM, Kazakoff S, Pearson JV, Waddell N, Allcock RJN, Holt RA, Robinson BWS, Creaney J. Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma. BMC Cancer. 2017 Jun2;17(1):396. doi: 10.1186/s12885-017-3382-6. PMID: 28577549; PMCID: PMC5455120.
• Creaney J, Dick IM, Leon JS, Robinson BW. A Proteomic Analysis of the Malignant Mesothelioma Secretome Using iTRAQ. Cancer Genomics Proteomics. 2017Mar-Apr;14(2):103-117. doi: 10.21873/cgp.20023. PMID: 28387650; PMCID:PMC5369310.
• Fisher SA, Aston WJ, Chee J, Khong A, Cleaver AL, Solin JN, Ma S, LesterhuisWJ, Dick I, Holt RA, Creaney J, Boon L, Robinson B, Lake RA. Transient Treg depletion enhances therapeutic anti-cancer vaccination. Immun Inflamm Dis. 2016Nov 21;5(1):16-28. doi: 10.1002/iid3.136. PMID: 28250921; PMCID: PMC5322183.
• Greening DW, Ji H, Chen M, Robinson BW, Dick IM, Creaney J, Simpson RJ. Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo. Sci Rep. 2016 Sep 8;6:32643. doi: 10.1038/srep32643. PMID:27605433; PMCID: PMC5015102.
• Creaney J, Dick IM, Musk AW, Olsen NJ, Robinson BW. Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers. Biomarkers. 2016 Sep;21(6):551-61. doi:10.3109/1354750X.2016.1160429. Epub 2016 Mar 24. PMID: 27009350.
• Robinson C, Dick IM, Wise MJ, Holloway A, Diyagama D, Robinson BW, CreaneyJ, Lake RA. Consistent gene expression profiles in MexTAg transgenic mouse andwild type mouse asbestos-induced mesothelioma. BMC Cancer. 2015 Dec 18;15:983.doi: 10.1186/s12885-015-1953-y. PMID: 26680231; PMCID: PMC4683914.
• Lesterhuis WJ, Rinaldi C, Jones A, Rozali EN, Dick IM, Khong A, Boon L,Robinson BW, Nowak AK, Bosco A, Lake RA. Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations. SciRep. 2015 Jul 21;5:12298. doi: 10.1038/srep12298. PMID: 26193793; PMCID:PMC4508665.
• Creaney J, Ma S, Sneddon SA, Tourigny MR, Dick IM, Leon JS, Khong A, FisherSA, Lake RA, Lesterhuis WJ, Nowak AK, Leary S, Watson MW, Robinson BW. Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen. Oncoimmunology. 2015 May 11;4(7):e1011492. doi: 10.1080/2162402X.2015.1011492.PMID: 26140232; PMCID: PMC4485777.
• Creaney J, Dick IM, Robinson BW. Comparison of mesothelin and fibulin-3 inpleural fluid and serum as markers in malignant mesothelioma. Curr Opin PulmMed. 2015 Jul;21(4):352-6. doi: 10.1097/MCP.0000000000000167. PMID: 26016578.
• Creaney J, Dick IM, Robinson BW. Discovery of new biomarkers for malignant mesothelioma. Curr Pulmonol Rep. 2015;4(1):15-21. doi:10.1007/s13665-015-0106-8. PMID: 25927434; PMCID: PMC4356891.
• Sneddon S, Leon JS, Dick IM, Cadby G, Olsen N, Brims F, Allcock RJ, MosesEK, Melton PE, de Klerk N, Musk AW, Robinson BW, Creaney J. Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma. Gene. 2015 May25;563(1):103-5. doi: 10.1016/j.gene.2015.03.031. Epub 2015 Mar 18. PMID:25796603.

ORCID profile

UWA research repository profile